Saturday, June 20, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 131 of 1,261
  1. US 11926656

    Antibodies and methods for the diagnosis and treatment of Epstein Barr Virus infection

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  2. US 11925686

    Materials for phototherapies of ophthalmic diseases

    EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  3. US 11925611

    Use of ZT-1A and analogs thereof to prevent and/or treat neurodegenerative and neurocognitive disorders

    United States Government as represented by the Department of Veterans Affairs · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  4. US 11925623

    Methods for the treatment of conditions related to hydrogen sulfide

    Regents of the University of Minnesota · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  5. US 11925616

    Compositions comprising urolithin compounds

    Amazentis SA · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  6. US 11926625

    HPK1 antagonists and uses thereof

    Nimbus Saturn, Inc. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  7. US 11925664

    Intracellular genomic transplant and methods of therapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  8. US 11925642

    Regulation of eIF4E activity for migraine therapy

    The Board of Regents of the University of Texas System · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  9. US 11925654

    Esters of 2-deoxy-monosaccharides with anti proliferative activity

    The Board of Regents of the University of Texas System · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  10. US 11925675

    Systemic delivery of adeno-associated virus vector expressing gamma-sarcoglycan and the treatment of muscular dystrophy

    Sarepta Therapeutics, Inc. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  11. US 11925685

    DNA antibody constructs encoding anti-ZIKV envelope antibodies

    Inovio Pharmaceuticals, Inc. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  12. US 11926826

    Twist signaling inhibitor compositions and methods of using the same

    The Regents of the University of California · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  13. US 11925669

    Chinese herbal medicine composition having a function of reducing uric acid

    INFINITUS (CHINA) COMPANY LTD. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  14. US 11926632

    Methods and compounds for restoring mutant p53 function

    PMV PHARMACEUTICALS, INC. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  15. US 11926622

    Fluoroalkyl-oxadiazoles and uses thereof

    Tenaya Therapeutics, Inc. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  16. US 11925706

    Manufacturing of bupivacaine multivesicular liposomes

    Pacira Pharmaceuticals, Inc. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  17. US 11926661

    Human antibodies to artemin and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  18. US 11926670

    Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  19. US 11926825

    Compounds and methods for reducing ATXN2 expression

    Ionis Pharmaceuticals, Inc. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  20. US 11926824

    miRNA biogenesis in exosomes for diagnosis and therapy

    The Board of Regents of the University of Texas System · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  21. US 11926832

    Ketohexokinase (KHK) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  22. US 11926828

    Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1

    Phio Pharmaceuticals Corp. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  23. US 11925629

    Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer

    Asana BioSciences, LLC · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  24. US 11925649

    Treatments for diabetic neuropathy

    The Regents of the University of California · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.